Fairfield Bush & CO. Has $3.31 Million Stake in Illumina, Inc. (ILMN)

Fairfield Bush & CO. cut its position in Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,059 shares of the life sciences company’s stock after selling 220 shares during the period. Illumina comprises 1.1% of Fairfield Bush & CO.’s portfolio, making the stock its 27th largest holding. Fairfield Bush & CO.’s holdings in Illumina were worth $3,307,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. DF Dent & Co. Inc. boosted its position in shares of Illumina by 10.1% during the second quarter. DF Dent & Co. Inc. now owns 467,789 shares of the life sciences company’s stock worth $81,171,000 after acquiring an additional 42,768 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Illumina by 2.1% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock worth $989,000 after acquiring an additional 116 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of Illumina during the second quarter worth $45,098,000. Caxton Associates LP bought a new position in shares of Illumina during the second quarter worth $312,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Illumina during the second quarter worth $1,889,000. 93.32% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Fairfield Bush & CO. Has $3.31 Million Stake in Illumina, Inc. (ILMN)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.com-unik.info/2017/10/10/fairfield-bush-co-has-3-31-million-stake-in-illumina-inc-ilmn.html.

ILMN has been the subject of a number of research reports. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 target price for the company. in a research report on Wednesday, June 21st. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $195.00 target price for the company in a research report on Thursday, July 27th. Canaccord Genuity upgraded shares of Illumina from a “hold” rating to a “buy” rating and upped their target price for the stock from $170.00 to $215.00 in a research report on Monday, August 7th. Argus upped their target price on shares of Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. Finally, First Analysis upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 target price for the company in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $184.86.

Illumina, Inc. (ILMN) traded down 0.29% during mid-day trading on Tuesday, reaching $202.69. 265,009 shares of the company were exchanged. The firm has a market capitalization of $29.59 billion, a P/E ratio of 40.67 and a beta of 0.76. The stock has a 50-day moving average of $202.97 and a 200 day moving average of $184.91. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $214.34.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. During the same period in the prior year, the firm earned $0.86 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Illumina, Inc. will post $3.65 earnings per share for the current year.

In other news, EVP Marc Stapley sold 2,000 shares of the stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $173.56, for a total value of $347,120.00. Following the completion of the sale, the executive vice president now directly owns 39,941 shares of the company’s stock, valued at $6,932,159.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the completion of the sale, the director now directly owns 534,176 shares of the company’s stock, valued at $91,221,235.52. The disclosure for this sale can be found here. Insiders sold 178,516 shares of company stock worth $34,995,591 over the last quarter. 1.60% of the stock is currently owned by insiders.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

What are top analysts saying about Illumina Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Illumina Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit